BioCentury on BioBusiness,
Finance
2012 IPOs outperforming 2011 deals; why Sofinnova is looking for queue to grow
Related tables, figures and sidebars
Glint of IPO optimism
By Stacy Lawrence
Senior Writer
Published on
Monday, August 6, 2012
Aftermarket performance is better for biotech IPOs this year
than it was in 2011. Although the basics of what it takes to get an IPO done
haven't changed - deals routinely continue to require a discount to the filing
range and substantial VC participation - Sofinnova
Ventures' James Healy is heartened by the deal flow he is seeing.
In aggregate, the IPO class of
2012 has gained 3%, and the class of 2011 has lost 3% since going public. The
differential is more stark if the change in value for each IPO is adjusted for
the change in value of the BioCentury 100 index since each company went public -
a calculation designed to factor out the general effect of the overall biotech
market. Based on that calculation, the class of 2012 is up 5% while the class
of 2011 is down 32%.
143
words displayed of
964
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]